IL6 and prostate carcinoma: However, most of the developed anti-IL-6 monoclonal antibodies have failed clinical trials against solid tumors, including pancreatic cancer, renal cell carcinoma, melanoma, prostate cancer, and colorectal cancer, and thus, they have never been approved for clinical use [71].